Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
---|---|---|---|---|---|---|
A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination | Roche | Completed | Bevacizumab | 3 | ML18147 | King Fahad Specialist Hospital (Dammam), King Abdulaziz Hospital and Oncology Center (Jeddah), King Abdulaziz University Hospital (Jeddah), King Faisal Specialist Hospital and Research Center (Jeddah), King Faisal Specialist Hospital and Research Center (Riyadh) |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) | BioMarin Pharmaceutical Inc. | Completed | BMN 110 | 3 | MOR-004 | King Faisal Specialist Hospital and Research Center (Riyadh) |
Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy | Roche | Completed | Tocilzumab | 3b | MA21573 | King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz University Hospital (Jeddah) |
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23 Valent pneumococcal polysacchride Vaccine. | Pfizer | Completed | 13-valent Pneumoccocal Conjugate Vaccine | 3 | B1851013 | King Faisal Specialist Hospital and Research Center (Riyadh) |